Carmot Therapeutics Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
70
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$3.3B
Carmot Therapeutics General Information
Description
Carmot Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes. It has three clinical-stage product candidates are: CT-388, a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist for the treatment of obesity and type 2 diabetes (T2D); CT-996, a once-daily oral, small molecule GLP-1 receptor agonist for the treatment of obesity and T2D; and CT-868, a once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist for the treatment of type 1 diabetes (T1D) patients with overweight or obesity.
Contact Information
Website
www.carmot.us(Operating Subsidiary)
Corporate Office
- 740 Heinz Avenue
- Berkeley, CA 94710
- United States
Carmot Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 26-Jan-2024 | $3.3B | 00000 | 00.00 | Completed | Clinical Trials - Phase 2 |
| 10. IPO | 17-Nov-2023 | Cancelled | Clinical Trials - Phase 2 | |||
| 9. Later Stage VC (Series E) | 25-May-2023 | 00000 | 00000 | 00.000 | Completed | Clinical Trials - Phase 2 |
| 8. Later Stage VC (Series D) | 25-Jul-2022 | 00000 | 00000 | 00000 | Completed | Clinical Trials - Phase 2 |
| 7. Later Stage VC (Series C) | 30-Sep-2020 | 000.00 | 000.00 | 00000 | Completed | Clinical Trials - Phase 2 |
| 6. Debt - PPP | 03-May-2020 | 000.00 | Completed | Clinical Trials - Phase 2 | ||
| 5. Later Stage VC (Series B) | 17-Jan-2018 | 0000 | 000.00 | 0000 | Completed | Pre-Clinical Trials |
| 4. Early Stage VC (Series A) | 17-Jul-2012 | 00.000 | 00.000 | 00.000 | Completed | Startup |
| 3. Grant | 08-Dec-2011 | $300K | $300K | Completed | Startup | |
| 2. Grant | 31-Dec-2010 | $440K | $300K | Completed | Startup |
Carmot Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | 0,000,000 | 00.000000 | 00.00 | 000.00 | 000.00 | 00 | 000.00 | 000 |
| Series D1 | 0,000,000 | 00.000000 | 00.0 | 000.00 | 000.00 | 00 | 000.00 | 0.000 |
| Series D | 0,000,000 | 00.000000 | 00.00 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
| Series C | 0,000,000 | 00.000000 | 00.00 | 000.00 | 000.00 | 00 | 000.00 | 0.000 |
| Series B | 1,977,878 | $0.001000 | $0.51 | $6.37 | $6.37 | 1x | $6.37 | 3.64% |
| Series A | 3,431,745 | $0.001000 | $0.05 | $0.63 | $0.63 | 1x | $0.63 | 6.32% |
Carmot Therapeutics Comparisons
Industry
Financing
Details
000000
000000
Carmot Therapeutics Competitors (2)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gelesis | Formerly VC-backed | Boston, MA | 00 | 00000 | 000000&0 | |
| Regulus Therapeutics | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
Carmot Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Carmot Therapeutics Patents
Carmot Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230151074-A1 | Modulators of g-protein coupled receptors | Pending | 13-May-2021 | 0000000000 | |
| AU-2022272251-A1 | Modulators of g-protein coupled receptors | Pending | 13-May-2021 | 0000000000 | |
| CA-3220005-A1 | Modulators of g-protein coupled receptors | Pending | 13-May-2021 | 0000000000 | |
| EP-4337682-A2 | Modulators of g-protein coupled receptors | Pending | 13-May-2021 | 0000000000 | |
| US-20220396569-A1 | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | Pending | 03-May-2021 | C07D405/14 | 0 |
Carmot Therapeutics Executive Team (10)
Carmot Therapeutics Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Aetna Trombley Ph.D | Self | Board Member | 000 0000 |
| Anne Phillips MD | Self | Board Member | 000 0000 |
| Charles Newton | BofA Securities | Board Member | 000 0000 |
| Heather Turner JD | Carmot Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
| Patrick Zhang | Horizons Ventures | Board Observer | 000 0000 |
Carmot Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Carmot Therapeutics Former Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| 5AM Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Amgen | Corporation | Minority | 000 0000 | 000000 0 | |
| Deep Track Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Franklin Templeton | Asset Manager | Minority | 000 0000 | 000000 0 | |
| Frazier Lifesciences Acquisition | Special Purpose Acquisition Company (SPAC) | Minority | 000 0000 | 000000 0 |
Carmot Therapeutics FAQs
-
When was Carmot Therapeutics founded?
Carmot Therapeutics was founded in 2008.
-
Who is the founder of Carmot Therapeutics?
Daniel Erlanson Ph.D and Stig Hansen Ph.D are the founders of Carmot Therapeutics.
-
Who is the CEO of Carmot Therapeutics?
Heather Turner JD is the CEO of Carmot Therapeutics.
-
Where is Carmot Therapeutics headquartered?
Carmot Therapeutics is headquartered in Berkeley, CA.
-
What is the size of Carmot Therapeutics?
Carmot Therapeutics has 70 total employees.
-
What industry is Carmot Therapeutics in?
Carmot Therapeutics’s primary industry is Biotechnology.
-
Is Carmot Therapeutics a private or public company?
Carmot Therapeutics is a Private company.
-
What is the current valuation of Carmot Therapeutics?
The current valuation of Carmot Therapeutics is 00.00.
-
What is Carmot Therapeutics’s current revenue?
The current revenue for Carmot Therapeutics is 000000.
-
How much funding has Carmot Therapeutics raised over time?
Carmot Therapeutics has raised $374M.
-
Who are Carmot Therapeutics’s investors?
5AM Ventures, Amgen, Deep Track Capital, Franklin Templeton, and Frazier Lifesciences Acquisition are 5 of 19 investors who have invested in Carmot Therapeutics.
-
Who are Carmot Therapeutics’s competitors?
Gelesis and Regulus Therapeutics are competitors of Carmot Therapeutics.
-
When was Carmot Therapeutics acquired?
Carmot Therapeutics was acquired on 26-Jan-2024.
-
Who acquired Carmot Therapeutics?
Carmot Therapeutics was acquired by Roche.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
